Lynk Pharmaceuticals Secures 322 Million RMB in Series C2 Funding

22 September 2023 | Friday | News

Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative clinical stage company, announced the successful completion of Series C2 financing.
Image Source : Public Domain

Image Source : Public Domain

This round of financing was jointly participated by the Shaoxing Binhai New Area Biomedical Industry Equity Investment Fund managed by China Grand Prosperity Investment, Haibang Venture and Howbuy Primary Fund, while original shareholders, New Alliance Capital and Lilly Asia Ventures (LAV), increased their investment. Following Series C1 financing on May 31, this new funding marks another step in the company's continuous growth, bringing the total amount raised in the C-round to 322 million RMB. HaoYue Capital acted as the exclusive financial advisor in this transaction.

Founded in 2018, Lynk Pharmaceuticals is a leading company dedicated to the research and development of FIC and BIC drugs targeting autoimmune diseases, inflammation, and oncology. Leveraging the core team's extensive background in medicinal chemistry, biology, clinical development, and commercial development, and with an average of more than 20 years of experience in new drug research and development, Lynk Pharmaceuticals focuses on innovative and differentiated pipeline development. The core of the pipeline is centered around the development of second-generation highly selective and third-generation tissue-specific JAK inhibitors, while also exploring the potential of innovative target-based drug development.

Since its establishment, efficient execution has propelled Lynk Pharmaceuticals rapid development. In the past three months, the Phase II clinical trial data for LNK01001 in rheumatoid arthritis, atopic dermatitis, and ankylosing spondylitis have been successively released, with all results demonstrating significant therapeutic effects and a high level of safety. These results highlight the characteristics of small molecule JAK1 inhibitors, that have quick onset action and excellent efficacy. The company has submitted applications for the End of Phase II (EOP2)/Pre-Phase III meeting; several indications are poised to enter Phase III clinical trials, aiming to benefit more patients as soon as possible. Additionally, first patient dosing was achieved in a Phase 1b trial of LNK01004 in both psoriasis and atopic dermatitis in the first half of this year. The early clinical trial data fromLNK01002 and LNK01003 are also promising while the pre-clinical pipeline development is progressing steadily as well.

Lynk Pharmaceuticals innovative research and clinical development capabilities have been continuously validated and enhanced, positioning the company for a crucial stage of rapid value growth. According to Frost & Sullivan's projections, the market size for JAK1 inhibitors is expected to reach $30.5 billion by 2030, underscoring the significant potential of the future market. Leveraging the considerable market demand in autoimmune diseases and oncology, the company holds substantial commercialization prospects.

Dr. Zhao-Kui (ZK) Wan, Chairman and CEO of Lynk Pharmaceuticals, said, "We are grateful for the support and trust from Shaoxing Binhai New Area Biomedical Industry Equity Investment Fund (managed by China Grand Prosperity Investment), New Alliance Capital, Fenghua Venture, Howbuy Primary Fund and Lilly Asia Ventures (LAV) for this round of investment. We also thank Tailong Capital and Liando Investment, the series C1 round investment institutions. Together they have helped us successfully complete the C round of financing. As a company focused on the treatment of autoimmune diseases and oncology, Lynk Pharmaceuticals is committed to developing globally competitive FIC/BIC innovative drugs and delivering differentiated and innovative therapeutic solutions to patients worldwide. We are pleased to see that even amidst the current challenges in the biopharmaceutical capital landscape, Lynk Pharmaceuticals continues to gain support from both new and existing shareholders, demonstrating the capital market's recognition of our team. During this rapid growing stage, we will need to consolidate resources from various aspects, further invest in clinical development, R&D teams, and technology platforms, aiming to provide safer and more effective innovative drugs to patients as early as possible. HaoYue Capital acted as the exclusive financial advisor for this financing, and we sincerely appreciate their professionalism and support."

Mr. Ding Yameng, Founding and Managing Partner and Chief Operating Officer of HaoYue Capital, said, "We are honored to continue assisting Lynk Pharmaceuticals in completing this round of financing. The field of autoimmune diseases is diverse and complex, with significant room for expanding indications and numerous unmet clinical needs, offering distinct opportunities for innovation. Lynk Pharmaceuticals has an internationally competitive and innovative pipeline that is continuously gaining market validation and recognition. We look forward to seeing breakthrough potentials in subsequent clinical validations of multiple highly differentiated candidates from Lynk. We believe that under the guidance of a highly capable and mission-driven team, Lynk Pharmaceuticals will steadily navigate through cycles, embrace the vast blue ocean markets, and provide better choices for patients soon."

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in